SFO
XLRN

Standard Family Office’s Acceleron Pharma XLRN Stock Holding History

Standard Family Office’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7
Closed -$1K – 656
2021
Q1 		$1K Buy
+7
New +$904 ﹤0.01% 611

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Standard Family Office's XLRN Position: Q2 2021 in Review

Standard Family Office sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 7 shares — an estimated $1K sold.

Standard Family Office first reported a position in XLRN in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

  • Standard Family Office reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
  • Standard Family Office sold 7 Acceleron Pharma shares in Q2 2021, an estimated $1K.
  • Standard Family Office first reported a position in Acceleron Pharma in Q1 2021 and held it in 1 quarter.
  • Standard Family Office's Acceleron Pharma position peaked at $1K in Q1 2021.
  • 271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on Standard Family Office's 13F filing for Q2 2021, filed 13 Aug 2021.